Celldex Therapeutics Inc. (NASDAQ:CLDX)’s share price fell 3.2% on Wednesday . The stock traded as low as $3.29 and last traded at $3.32, with a volume of 1,824,487 shares changing hands. The stock had previously closed at $3.43.

Several brokerages have weighed in on CLDX. Wedbush reaffirmed a “neutral” rating and issued a $3.00 price objective on shares of Celldex Therapeutics in a report on Friday, May 6th. Jefferies Group reaffirmed a “hold” rating and issued a $5.00 price objective (up from $4.00) on shares of Celldex Therapeutics in a report on Thursday, August 11th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, June 7th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Celldex Therapeutics has an average rating of “Hold” and a consensus price target of $10.75.

The firm has a 50 day moving average price of $4.32 and a 200 day moving average price of $4.50. The stock’s market cap is $333.81 million.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.02. The firm had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.96 million. Celldex Therapeutics’s revenue for the quarter was down 36.4% on a year-over-year basis. During the same period last year, the company posted ($0.33) earnings per share. Equities research analysts forecast that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.